The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
David H. Lawson
Consultant or Advisory Role - Castle Biosciences (U)
Research Funding - Castle Biosciences
Maria C. Russell
No relevant relationships to disclose
Jeff Wilkinson
No relevant relationships to disclose
Gilchrist L. Jackson
No relevant relationships to disclose
Anthony Greisinger
No relevant relationships to disclose
Rodale N Amaria
No relevant relationships to disclose
Rene Gonzalez
No relevant relationships to disclose
Stephen Lyle
Honoraria - Castle Biosciences
Clare Johnson
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Kristen M. Oelschlager
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
John F Stone
No relevant relationships to disclose
Derek Maetzold
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Robert W. Cook
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Laura Ferris
No relevant relationships to disclose
Keith A. Delman
No relevant relationships to disclose
Pedram Gerami
Consultant or Advisory Role - Castle Biosciences
Honoraria - Castle Biosciences
Research Funding - Castle Biosciences